The goal of this clinical trial is to learn if naltrexone works to treat nonsuicidal self-injurious behavior in adolescents and adults.
Recruiting participants with nonsuicidal self-injurious behavior and randomizing them to the experiment group and the control group at a 1:1 ratio, the test group administers the experiment drug naltrexone along with the general treatment, and the control group provides a placebo. Clinical evaluation including the frequency of self-injurious behavior is conducted every two weeks. The investigator and participants will double-blinded. Analyze the relationship between changes in clinical symptoms and socio-demographic characteristics, diagnosis, clinical characteristics, and anticipated to discover predictors of treatment effectiveness.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
150
naltrexone 50mg for 6 weeks
placebo for 6 weeks
Seoul National University Hospital
Seoul, South Korea
Frequency of nonsuicidal self-injurous behavior
Total number of nonsuicidal self-injurous behavior during study period
Time frame: 6 weeks
Deliberate Self-harm Inventory
change of NSSI frequency acquired by Deliberate Self-harm Inventory (the outcome of this scale does not have score)
Time frame: 6 weeks
Clinical Global Impressions
change of Clinical Global Impressions scale the minimum and maximum values are 1 to 7, higher scores mean worse outcome
Time frame: 6 weeks
Obsessive Compulsive Drinking Scale
change of Obsessive Compulsive Drinking Scale the minimum and mixiumum values are 0 to 40, higher scores mean a worse outcome
Time frame: 6 weeks
Eating Disorder Examination-Questionnaire
change of Eating Disorder Examination-Questionnaire the minimum and mixiumum values are 0 to 6, higher scores mean a worse outcome
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.